From OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders
September 10, 2020
The American Cancer Society estimates that approximately 25 percent of people diagnosed with kidney (renal) cancer in the U.S. will die from the disease. This number has not changed for many years.
One reason patients with renal cancer are not surviving is because it typically isn’t diagnosed until it has advanced. Contributing factors to late diagnosis include:
- These cancers can sometimes grow quite large without causing any pain or other problems.
- The kidneys are deep inside the body, so small kidney tumors cannot be seen or felt during a physical exam.
- There are no recommended screening tests for kidney cancer in people who are not at increased risk. This is because no test has been shown to lower the overall risk of dying from kidney cancer.
Since there is no screening to detect renal cancer at an early stage, doctors at OHC continue to search for new treatments that are effective when the cancer is diagnosed.
“As with most cancers, the later it is detected, the more difficult it is to treat, and renal cancer is no exception. And because it doesn’t often present symptoms in earlier stages, we continue our work to find new and better treatment options for patients whose cancer is in a late stage. And that’s what we’re doing at OHC through our clinical trials program,” says David M. Waterhouse, MD, MPH, internationally noted medical oncologist, hematologist and co-director of the research department at OHC.
Cancer researchers at OHC are evaluating a promising new treatment that could help improve the outcomes for patients with kidney cancer and offer hope for remission. This new treatment is an inhibitor drug called MK-6482, which stops the proteins responsible for the growth of renal cancer tumors.
“Our cells have a protein called VHL. If VHL is deactivated, another protein called HIF-2a can accumulate and lead to the formation of both cancerous and non-cancerous tumors,” Dr. Waterhouse explained. “HIF-2a is very difficult to target and treat until MK-6482. This drug has demonstrated an ability to stop the HIF-2a proteins, which in turn stops the growth of the tumor.
“This is one of the most promising treatments in development for kidney cancer and OHC is the only cancer practice in the region, and one of only two in Ohio, to make this available for patients.”
OHC brings new, innovative treatments to cancer patients, offering hope for remission and a return to the activities they enjoyed before cancer. Learn more about leading-edge treatments and services at OHC, or request a second opinion, at ohcare.com or call 1-888-649-4800.Comments (0)